Endurant Capital Management LP Viking Therapeutics, Inc. Transaction History

Endurant Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $538,528 - $899,604	-36,289 Reduced 63.62%	20,754 $336,000
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $3.04 Million - $6.52 Million	-375,992 Reduced 86.83%	57,043 $949,000
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $1.18 Million - $4.07 Million	433,035 New	433,035 $4.07 Million
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $1.37 Million - $1.9 Million	-178,448 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $947,363 - $1.24 Million	124,982 Added 233.76%	178,448 $1.77 Million
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $132,538 - $300,063	-18,511 Reduced 25.72%	53,466 $409,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $111,336 - $225,542	11,478 Added 18.97%	71,977 $1.25 Million
Q2 2018 Aug 14, 2018	SELL	$3.88 - $12.74 $227,371 - $746,576	-58,601 Reduced 49.2%	60,499 $574,000
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $489,501 - $825,363	119,100 New	119,100 $520,000

478

66.1M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.